Vasoactive Intensity Predicts Mortality Beyond SCAI Staging in Cardiogenic Shock

Abstract Background Cardiogenic shock (CS) remains associated with high mortality. Severity is traditionally stratified by the SCAI staging system despite substantial heterogeneity within stages. Whether vasoactive therapy intensity or combination provides additional prognostic information beyond SCAI staging remains unknown. This study assessed whether vasoactive support intensity, quantified by the vasoactive–inotropic score (VIS), improves mortality prediction beyond SCAI staging. Methods In this retrospective bicentric cohort, consecutive adults admitted for CS between 2018 and 2023 were included. The VIS was calculated. The primary outcome was 90-day mortality. Multivariable logistic regression models adjusted for baseline severity assessed interactions with SCAI stage and the incremental prognostic value of VIS using nested models. Results Among 1,167 patients, 90-day mortality increased across SCAI stages C, D, and E (20.1%, 27.4%, and 45.6%; p<0.001, respectively), with substantial heterogeneity within stages. In stage C, dobutamine alone was associated with lower mortality than norepinephrine alone (OR=0.25[0.09–0.74]; p=0.009); in stage E, dobutamine plus norepinephrine was associated with higher mortality (OR=2.39[1.07–5.36]; p=0.028). The number of vasoactive agents was associated with mortality (OR=1.27 per additional agent; p=0.041) but proved a crude marker, providing only marginal incremental discrimination (R2=0.233; Δ=+0.011), with its prognostic information fully captured by VIS (R2=0.286 vs 0.287 with and without number of agents). Adding SCAI stage minimally improved discrimination (R2=0.222 to 0.226; Δ=+0.004), whereas VIS substantially improved model performance (R2=0.286; Δ=+0.060;p<0.001). Conclusion Vasoactive intensity quantified by the vasoactive–inotropic score improved 90-day mortality prediction beyond SCAI staging and the simple count of vasoactive drugs, providing incremental prognostic information beyond SCAI staging.

Authors

Institutions

Publication Details

Journal
European Heart Journal Open
Published
2026-08-17
DOI
https://doi.org/10.1093/ehjopen/oeag126
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Vasoactive Intensity Predicts Mortality Beyond SCAI Staging in Cardiogenic Shock

François Roubille, Yazine Mahjoub, Pierre‐Grégoire Guinot, Osama Abou‐Arab et al.
European Heart Journal Open
Mechanical Circulatory Support Devices
article

Vasoactive Intensity Predicts Mortality Beyond SCAI Staging in Cardiogenic Shock

François Roubille, Yazine Mahjoub, Pierre‐Grégoire Guinot, Osama Abou‐Arab, Christophe Beyls, Nicolas Mollet, Nathan Helstroffer, Bélaïd Bouhemad
article en

Abstract

Abstract Background Cardiogenic shock (CS) remains associated with high mortality. Severity is traditionally stratified by the SCAI staging system despite substantial heterogeneity within stages. Whether vasoactive therapy intensity or combination provides additional prognostic information beyond SCAI staging remains unknown. This study assessed whether vasoactive support intensity, quantified by the vasoactive–inotropic score (VIS), improves mortality prediction beyond SCAI staging. Methods In this retrospective bicentric cohort, consecutive adults admitted for CS between 2018 and 2023 were included. The VIS was calculated. The primary outcome was 90-day mortality. Multivariable logistic regression models adjusted for baseline severity assessed interactions with SCAI stage and the incremental prognostic value of VIS using nested models. Results Among 1,167 patients, 90-day mortality increased across SCAI stages C, D, and E (20.1%, 27.4%, and 45.6%; p<0.001, respectively), with substantial heterogeneity within stages. In stage C, dobutamine alone was associated with lower mortality than norepinephrine alone (OR=0.25[0.09–0.74]; p=0.009); in stage E, dobutamine plus norepinephrine was associated with higher mortality (OR=2.39[1.07–5.36]; p=0.028). The number of vasoactive agents was associated with mortality (OR=1.27 per additional agent; p=0.041) but proved a crude marker, providing only marginal incremental discrimination (R2=0.233; Δ=+0.011), with its prognostic information fully captured by VIS (R2=0.286 vs 0.287 with and without number of agents). Adding SCAI stage minimally improved discrimination (R2=0.222 to 0.226; Δ=+0.004), whereas VIS substantially improved model performance (R2=0.286; Δ=+0.060;p<0.001). Conclusion Vasoactive intensity quantified by the vasoactive–inotropic score improved 90-day mortality prediction beyond SCAI staging and the simple count of vasoactive drugs, providing incremental prognostic information beyond SCAI staging.

European Heart Journal Open
Centre National de la Recherche Scientifique (FR), Inserm (FR), Physiologie et Médecine Expérimentale du Coeur et des Muscles (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Université Bourgogne Franche-Comté (FR), Centre de recherche Translationnelle en Médecine moléculaire (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Université de Picardie Jules Verne (FR)
Reduced inequalities
Openalex Percentile: Top 18%
Mechanical Circulatory Support Devices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.